IDEAS home Printed from https://ideas.repec.org/a/lus/zwipol/v54y2005i3p366-390n6.html
   My bibliography  Save this article

Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie

Author

Listed:
  • Mahlich Jörg

    (Wirtschaftskammer Österreich, Stabsabteilung Wirtschaftspolitik,Wiedner Hauptstrasse 63, A–1045 Wien)

Abstract

Against the background of decreasing competitiveness of German pharmaceutical firms, we analyze the impact of institutional framework conditions on the performance of research-based pharmaceutical enterprises. Reviewing the literature, we find ample empirical evidence that both strict price regulation and a rigorous drug approval process lower the expected returns of new drug introductions and therefore reduce the incentives of R&D investments. A reliable patent system on the other hand constitutes a regulatory measure that enhances firm R&D investments and thereby generates a positive economic impact.

Suggested Citation

  • Mahlich Jörg, 2005. "Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie," Zeitschrift für Wirtschaftspolitik, De Gruyter, vol. 54(3), pages 366-390, December.
    • Handle: RePEc:lus:zwipol:v:54:y:2005:i:3:p:366-390:n:6
    DOI: 10.1515/zfwp-2005-0306
    as

    Download full text from publisher

    File URL: https://doi.org/10.1515/zfwp-2005-0306
    Download Restriction: For access to full text, subscription to the journal or payment for the individual article is required.
    File URL: https://libkey.io/10.1515/zfwp-2005-0306?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Mahlich, Jörg C. & Yurtoglu, Burcin, 2011. "Intangibles Kapital und Rentabilität in der Pharmaindustrie," Die Unternehmung - Swiss Journal of Business Research and Practice, Nomos Verlagsgesellschaft mbH & Co. KG, vol. 65(1), pages 32-49.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:lus:zwipol:v:54:y:2005:i:3:p:366-390:n:6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Peter Golla (email available below). General contact details of provider: https://www.degruyter.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.